The Sajni Chakrabarti Fund for Pediatric Brain Cancer Research's Fundraising Page

Sajni (right) and Anandi
Sajni (right) and Anandi

WHY WE'RE FUNDRAISING WITH THE JIMMY FUND WALK TO FIGHT CANCER

About Sajni

Our warm, smart, bright-eyed Sajni, together with her sister Anandi, was our pride and joy.   At seven, Sajni was diagnosed with a brain tumor called DIPG for which, currently, there is no effective treatment.  She demonstrated her courage and grace throughout 19 months of treatment in England and at Dana Farber, and passed away on July 1, 2017.   We are bereft from our loss, and have started the fund to find a treatment and ultimately a cure. DIPG is the deadliest pediatric brain tumor, as 250 children in the US die every year.  Other pediatric brain tumors take the lives of many more children.  We need your help - today -  to advance the effort and save the lives of children.  Some other cancers have now found treatments, but only investment from people like you can fund the necessary research on pediatric brain tumors. 

We thank you for your generosity. Every dollar can help. 

- Prabal and Vanessa - parents of Anandi (11), Remi (5) and Sajni (forever)


We hope you will consider making a gift to this page and build upon the amazing work already started to support Dr. Filbin and her research.

 

 

 

About the Fund: What your dollars support

The Sajni Fund has helped fund work that is currently under consideration at "Cancer Discovery" and "The New England Journal of Medicine" and identified key potential targets through two large-scale drug and genetic screens. First, Dr. Filbin tested drugs from the National Cancer Institute’s compound library, a repository of approximately 3,000 agents thought to have anti-cancer effects. Filbin also performed a genetic screen using a type of advanced genome-technology, called CRISPR, that tested the effect of epigenetic genes in DIPG cell lines. Combining these approaches led Filbin to identify several novel targets in DIPG, one of which is already being tested in patients with DIPG and has shown promising results in two patients on this clinical trial. 

Through her work, Dr. Filbin aims to understand the function of these novel targets in DIPG, which could point the way to biomarkers that predict patients' responses. Dr. Filbin and her team are also exploring how these novel targets might be combined to boost their efficacy and circumvent drug resistance, which is much more common in single-drug approaches. Dr. Filbin aims to bring the best combinations forward into clinical trials for patients with DIPG, starting at the Dana-Farber Cancer Institute, and then expanding to national and international clinical trials.​

 

 

 

PROGRESS TO GOAL

Raised:$112,415.89
Goal:$0
1team member

THANK YOU TO OUR TEAM MEMBERS

C = Team Captain
NAME
AMOUNT RAISED
x0x
x$112,415.89x

THANK YOU TO OUR TEAM DONORS

NAME
AMOUNT
Event Honor Roll
Nellie Mae Education Foundation
$10,000
Amy and Charlie Burrows
$30
Amy Sherr
$54
Anonymous
Beecher Grogan
$100
Bristol-Myers Squib for Sharon Cload
$2,060
Caitlin and Niamh
Caroline Ellis
$100
Casey Breton & Eliran Boraks
Dara Arons & Leah McDiarmid
$500
David Tierney
$500
Dr. Lynne Golomb
Forward Financing for Casey Breton
$103
Go, Rose.
$100
In honor of Leah McDiarmid's Bat Mitzvah
In Honor of Leah McDiarmid's Bat Mitzvah from the Perskie Family
In Honor of Leah S. McDiarmid's Bat Mitzvah
In honor of Leah Sohn McDiarmid, from JoLynn & Byron Gustin
In Honot of Leah McDiarmid's Bat Mitzvah Oct 2023
$257
JACQUELINE PALLADINO
$100
Jeanne and Steve MacNevin
$100
Jimmy Fund Walk 2021
Jimmy Fund Walk 2022
Jonathan Wall
Kush Jhawar and Priya Patel
$1,545
Lizanne Kindler
$515
Maggie & Bruce Church
$50
Margaret & David McDiarmid
Marguerite Brackley & Kunal Jajoo
Martha Jane Phelps
$103
Mayya Shtokman
Mr. arvind krishnamurthy
$150
Mr. Burks Oakley II and Mrs. Loretta Bowen Oakley
Ms. Caitlin Roberts
$100
Ms. Cathy Spear
Ms. Talaya Delaney
Ms. Vanessa Ruget
$32,500
Rachel Weinstein
Robert Adelberg
$100
Robert Adelberg
S Cload
$2,060
Sascha McHugh
$100
Seema Sheth-Voss
$50
Shea Family
$100
Syeda Fatima
Thalia Tringo; in honor of Karina Funk and Kurt Hanson
$250
Ullmann Family in celebration of Leah McDiarmid
$100
Vanessa Ruget & Prabal Chakrabarti
$20,000
Vanessa Ruget & Prabal Chakrabarti for Sajni Chakrabarti
$2,000
I'm Living Proof buttons
Every dollar raised helps fuel Dana-Farber Cancer Institute's mission.
Together, we can defy cancer!














My Giving Page

Sajni (right) and Anandi
Sajni (right) and Anandi

The Sajni Chakrabarti Fund for Pediatric Brain Cancer Research

About Sajni

Our warm, smart, bright-eyed Sajni, together with her sister Anandi, was our pride and joy.   At seven, Sajni was diagnosed with a brain tumor called DIPG for which, currently, there is no effective treatment.  She demonstrated her courage and grace throughout 19 months of treatment in England and at Dana Farber, and passed away on July 1, 2017.   We are bereft from our loss, and have started the fund to find a treatment and ultimately a cure. DIPG is the deadliest pediatric brain tumor, as 250 children in the US die every year.  Other pediatric brain tumors take the lives of many more children.  We need your help - today -  to advance the effort and save the lives of children.  Some other cancers have now found treatments, but only investment from people like you can fund the necessary research on pediatric brain tumors. 

We thank you for your generosity. Every dollar can help. 

- Prabal and Vanessa - parents of Anandi (11), Remi (5) and Sajni (forever)


We hope you will consider making a gift to this page and build upon the amazing work already started to support Dr. Filbin and her research.

 

 

 

About the Fund: What your dollars support

The Sajni Fund has helped fund work that is currently under consideration at "Cancer Discovery" and "The New England Journal of Medicine" and identified key potential targets through two large-scale drug and genetic screens. First, Dr. Filbin tested drugs from the National Cancer Institute’s compound library, a repository of approximately 3,000 agents thought to have anti-cancer effects. Filbin also performed a genetic screen using a type of advanced genome-technology, called CRISPR, that tested the effect of epigenetic genes in DIPG cell lines. Combining these approaches led Filbin to identify several novel targets in DIPG, one of which is already being tested in patients with DIPG and has shown promising results in two patients on this clinical trial. 

Through her work, Dr. Filbin aims to understand the function of these novel targets in DIPG, which could point the way to biomarkers that predict patients' responses. Dr. Filbin and her team are also exploring how these novel targets might be combined to boost their efficacy and circumvent drug resistance, which is much more common in single-drug approaches. Dr. Filbin aims to bring the best combinations forward into clinical trials for patients with DIPG, starting at the Dana-Farber Cancer Institute, and then expanding to national and international clinical trials.​

 

 

 

View More
View More